CROI 2026 Analysis (Presented Earlier in 2026 at the Conference on Retroviruses and Opportunistic Infections) Documents That GLP-1 Weight-Loss Medications Generally Work Well for People Living With HIV on Antiretroviral Therapy and May Improve Liver, Gut, and Cardiovascular Health While Reducing Smoking Rates Alongside the Known Obesity and Diabetes Benefits; Real-World Analysis of People With HIV Prescribed Semaglutide (Wegovy, Ozempic) or Tirzepatide (Mounjaro, Zepbound) Documented Comparable Weight Loss to the General-Population Trial Data With No New Safety Signals Specific to the HIV Population, Making GLP-1 Therapy a Reasonable Consideration in the Approximately 40% of People Living With HIV in the US Who Also Have Obesity
A CROI 2026 (Conference on Retroviruses and Opportunistic Infections) analysis presented earlier in 2026 documented that GLP-1 weight-loss medications generally work well for people living with HIV who are stable on antiretroviral therapy. Beyond the known obesity and type 2 diabetes benefits, the CROI analysis reported potential improvements in liver, gut, and cardiovascular health, plus reduced smoking rates in the HIV population on GLP-1 therapy. Real-world analysis of people living with HIV prescribed semaglutide (Wegovy, Ozempic) or tirzepatide (Mounjaro, Zepbound) documented comparable weight loss to general-population Phase 3 trial data with no new safety signals specific to the HIV population. Approximately 40% of people living with HIV in the US also have obesity, and cardiovascular disease is one of the primary drivers of morbidity and mortality in the HIV-treated population. The CROI analysis supports GLP-1 therapy as a reasonable consideration in HIV patients with obesity or metabolic-syndrome comorbidities, particularly following the AIDS 2026 conference programming that concluded Friday July 31 in Rio de Janeiro emphasizing the sustained management of HIV alongside comorbid conditions in the current global funding-constrained environment. The finding also intersects with the ongoing peptide-adjacent HIV therapeutic landscape covered by the July 2026 Gilead-Merck ISLEND-1 and ISLEND-2 once-weekly islatravir/lenacapavir data and the Merck alimatravir monthly HIV prevention pill.